HC Wainwright Analysts Lift Earnings Estimates for TCRX

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Investment analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for shares of TScan Therapeutics in a report issued on Tuesday, September 8th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.08) per share for the quarter, up from their prior estimate of ($0.22). HC Wainwright has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.11) per share. HC Wainwright also issued estimates for TScan Therapeutics’ Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.62) EPS, FY2027 earnings at ($0.27) EPS, FY2028 earnings at ($0.24) EPS and FY2029 earnings at ($0.24) EPS.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.02. TScan Therapeutics had a negative return on equity of 108.72% and a negative net margin of 1,655.35%.The business had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $1.88 million.

TCRX has been the topic of several other reports. Wedbush lowered shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price on the stock. in a research report on Wednesday, September 2nd. Needham & Company LLC reissued a “buy” rating and set a $6.00 price target on shares of TScan Therapeutics in a research note on Tuesday, June 23rd. Lifesci Capital cut TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 2nd. Weiss Ratings cut TScan Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Finally, Benchmark reiterated a “buy” rating on shares of TScan Therapeutics in a research report on Thursday, August 13th. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $2.67.

TScan Therapeutics Price Performance

Shares of NASDAQ TCRX opened at $0.33 on Thursday. The company’s fifty day moving average is $0.79 and its two-hundred day moving average is $0.97. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.37 and a current ratio of 3.37. The firm has a market capitalization of $22.37 million, a P/E ratio of -0.36 and a beta of 1.07. TScan Therapeutics has a one year low of $0.33 and a one year high of $2.57.

Institutional Investors Weigh In On TScan Therapeutics

A number of large investors have recently bought and sold shares of TCRX. BlackRock Inc. acquired a new stake in TScan Therapeutics during the second quarter worth approximately $975,000. GSA Capital Partners LLP acquired a new stake in shares of TScan Therapeutics during the second quarter worth $537,000. Renaissance Technologies LLC boosted its holdings in shares of TScan Therapeutics by 37.5% during the fourth quarter. Renaissance Technologies LLC now owns 1,141,069 shares of the company’s stock worth $1,141,000 after purchasing an additional 311,150 shares during the last quarter. Jane Street Group LLC grew its position in shares of TScan Therapeutics by 377.5% in the fourth quarter. Jane Street Group LLC now owns 388,284 shares of the company’s stock valued at $388,000 after purchasing an additional 306,968 shares during the period. Finally, Marshall Wace LLP increased its stake in TScan Therapeutics by 627.5% in the fourth quarter. Marshall Wace LLP now owns 339,240 shares of the company’s stock valued at $339,000 after purchasing an additional 292,610 shares during the last quarter. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.